Reduced Hippocampal Dendrite Branching, Spine Density and Neurocognitive Function in Premature Rabbits, and Reversal

Damon Klebe1,2, Mahima Tibrewal3, Deep R Sharma1,2

  • 1Department of Pediatrics, Albert Einstein College of Medicine, Bronx NY, USA.

Insights

Premature birth and lack of maternal care impair neurobehavioral function and brain development in preterm infants. Treatments with 17β-estradiol (E2) or 7,8-dihydroxyflavone (DHF) show potential to reverse these deficits.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Pediatrics

Background:

  • Preterm birth is associated with neurological and behavioral disorders.
  • Non-maternal care in preterm infants may negatively impact neurodevelopment.
  • The role of 17β-estradiol (E2) and TrkB agonists in mitigating these effects is under investigation.

Purpose of the Study:

  • To investigate the impact of premature birth and non-maternal care on neurobehavioral function and hippocampal dendritic development.
  • To assess the potential of E2 replacement or 7,8-dihydroxyflavone (DHF) to reverse these deficits in preterm newborns.

Main Methods:

  • Comparison of preterm (E28.5) rabbit kits under non-maternal care with term-born controls.
  • Neurobehavioral testing, assessment of hippocampal dendritic arborization and spine density.
  • Analysis of CDC42, Rac1/2/3, and RhoA signaling pathways.
  • Evaluation of E2 and DHF treatments on neurodevelopmental outcomes.

Main Results:

  • Preterm birth and non-maternal care led to increased anxiety, poor social interaction, and reduced novelty preference.
  • Reduced dendritic branching and spine density were observed in the CA1 hippocampus of preterm kits.
  • E2 and DHF treatments reversed reduced spine density, normalized RhoA signaling, and improved cognitive function.

Conclusions:

  • Prematurity and non-maternal care contribute to cognitive deficits and impaired hippocampal development.
  • E2 replacement or DHF treatment may offer therapeutic potential for improving neurodevelopmental outcomes in premature infants.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
493
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
898
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.9K
Reducing Line Loss01:18

Reducing Line Loss

In a three-phase circuit, line loss is an indicator of energy dissipated as heat due to the resistance of transmission lines. To address this, incorporating transformers into the system—a step-up transformer at the source and a step-down transformer at the load—is a strategic solution. Two three-phase transformers are introduced to improve this.
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
384
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.6K